Shandong Weigao Blood Purification Products Co., Ltd. (SHA:603014)
China · Delayed Price · Currency is CNY 35.00
+0.55 (1.60%)
At close: Nov 13, 2026
SHA:603014 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 12, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 14,621 | 16,556 | - | - | - | - | |
Market Cap Growth | -18.85% | - | - | - | - | - |
Enterprise Value | 11,091 | 13,945 | - | - | - | - |
Last Close Price | 35.00 | 38.96 | - | - | - | - |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 12, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 21.48 | 34.33 | - | - | - | - |
Forward PE | 29.05 | 31.27 | - | - | - | - |
PS Ratio | 2.71 | 4.39 | - | - | - | - |
PB Ratio | 1.34 | 2.33 | - | - | - | - |
P/TBV Ratio | 1.39 | 2.42 | - | - | - | - |
P/FCF Ratio | 13.99 | 26.12 | - | - | - | - |
P/OCF Ratio | 11.74 | 20.86 | - | - | - | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 12, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 2.05 | 3.70 | - | - | - | - |
EV/EBITDA Ratio | 7.86 | 17.82 | - | - | - | - |
EV/EBIT Ratio | 9.69 | 25.70 | - | - | - | - |
EV/FCF Ratio | 10.61 | 22.00 | - | - | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 12, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.02 | 0 | 0.00 | 0.00 | 0.01 | 0.22 |
Debt / EBITDA Ratio | 0.13 | 0.00 | 0.01 | 0.01 | 0.08 | 1.45 |
Debt / FCF Ratio | 0.17 | 0.01 | 0.03 | 0.19 | 0.10 | 7.73 |
Net Debt / Equity Ratio | -0.32 | -0.39 | -0.20 | -0.14 | -0.12 | 0.13 |
Net Debt / EBITDA Ratio | -2.54 | -3.58 | -1.52 | -1.00 | -0.99 | 0.85 |
Net Debt / FCF Ratio | -3.38 | -4.42 | -2.89 | -12.82 | -1.23 | 4.43 |
Asset Turnover | 0.51 | 0.48 | 0.53 | 0.54 | 0.56 | - |
Inventory Turnover | 2.86 | 2.86 | 2.52 | 2.55 | 3.21 | - |
Quick Ratio | 3.04 | 2.65 | 1.60 | 1.14 | 1.03 | 0.62 |
Current Ratio | 3.94 | 3.30 | 2.27 | 1.82 | 1.49 | 0.92 |
Return on Equity (ROE) | 11.26% | 7.59% | 8.37% | 9.02% | 7.55% | - |
Return on Assets (ROA) | 6.73% | 4.35% | 4.71% | 4.55% | 3.25% | - |
Return on Invested Capital (ROIC) | 16.42% | 10.36% | 9.54% | 9.43% | 6.70% | 6.90% |
Return on Capital Employed (ROCE) | 10.30% | 7.50% | 9.10% | 9.10% | 6.70% | 9.30% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 12, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 4.65% | 2.91% | - | - | - | - |
FCF Yield | 7.15% | 3.83% | - | - | - | - |
Dividend Yield | 1.48% | 1.31% | - | - | - | - |
Payout Ratio | 30.30% | 13.65% | - | 0.11% | 5.98% | 16.44% |
Buyback Yield / Dilution | -56.84% | -6.45% | -0.30% | -1.76% | -3.63% | - |
Total Shareholder Return | -55.36% | -5.14% | -0.30% | -1.76% | -3.63% | - |